Home / Companies / Medreg S.R.O.
Company family
Medreg S.R.O.: medicine shortages
As of 2 Nov 2026, 12 Medreg S.R.O. products have a reported shortage across 1 countries, covering 8 medicines.
Products short12rank #157 of 464
Medicines8active ingredients
Countries1/16
New in 90 days6+2 vs market pace
Typical duration54 daysmedian so far
Manufacturing33%demand-driven 0%
Where
Which therapeutic classes
Why, compared with all companies
Manufacturing problemIncreased demandActive ingredient shortageDistribution or logisticsCommercial decision or withdrawalRegulatory or licensingOtherNot stated
Manufacturing problems point to the company's own supply chain; increased demand often follows a competitor's shortage or a demand shock.
When its current shortages began
Against its peers
Breadth vs depth
Further right: more products short. Higher: more different medicines affected.
Medicines short
| Medicine | Where this company is short | Products | Earliest start | Main reason | Short anywhere |
|---|---|---|---|---|---|
| Levocetirizine | 3 | 9 Mar 2026 | Manufacturing problem | 4/16 | |
| Candesartan and Diuretics | 2 | 27 Oct 2026 | Manufacturing problem | 5/16 | |
| Pregabalin | 2 | 18 May 2026 | Commercial decision or withdrawal | 11/16 | |
| Atorvastatin | 1 | 19 Oct 2026 | Commercial decision or withdrawal | 11/16 | |
| Candesartan | 1 | 26 Jan 2026 | Distribution or logistics | 10/16 | |
| Escitalopram | 1 | 20 Dec 2026 | Commercial decision or withdrawal | 10/16 | |
| Montelukast | 1 | 17 Aug 2026 | Commercial decision or withdrawal | 13/16 | |
| Urapidil | 1 | 1 Oct 2026 | Commercial decision or withdrawal | 4/16 |
Shortage data describes supply, not company finances. A shortage can mean lost sales for the supplier or extra demand for its competitors. Nothing here is investment advice; tickers are for identification only and may be out of date.